PHARMA DEALS DURING JUNE 2014 

(Part 3 out of 3)
by Medius Associates

This table lists all the major pharma collaborations, acquisitions and mergers agreed during June 2014

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Covidien/ Medtronic	Company acquisition	Medical device company adding US critical mass	42,900
Idenix Pharmaceuticals/ Merck & Co	Company acquisition	Hepatitis C assets include IDX21437 (p1/2 nucleotide inhibitor) to combine with Merck HCV drugs	3,850
Labrys Biologics/ Teva	Company acquisition	Includes Labrys' p2b anti-CGRP mAb for treatment of episodic migraine	825
Chelsea Therapeutics/ Lundbeck	Company acquisition	Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved)	658
OAO Veropharm/ Abbott Laboratories	Company acquisition	Russian based manufacturing company	630
DAVA Pharmaceuticals/ Endo International	Company acquisition	Generics business including generic Doxycycline and Cefdinir	575
Bionomics/ Merck & Co	Exclusive research and licence agreement	BNC 375 in Alzheimer's disease (preclinical)	526
Adaptimmune/ GSK	Co-development and  option	TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2)	350
Genia Technologies/ Roche	Company acquisition	Single molecule, semiconductor, DNA sequencing using nanopore technology	350
Medreich/ Meiji Seika	Company acquisition	India-based manufacturing company	290
Cellectis/ Pfizer	Collaboration	Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at multiple selected oncology targets (platform)	265* +  $28m equity
Dimension Therapeutics/ Bayer	Licence	Gene  therapy for the treatment of haemophilia A (preclinical)	252
Synairgen/ AstraZeneca	Exclusive global licence	SNG 001 inhaled beta interferon (p2)	232
Ligand Pharmaceuticals/ TG Therapeutics	Exclusive global licence	Development, commercialisation of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors (preclinical)	208
Pregenen/ bluebird bio	Company acquisition	Gene editing technology platform	156
OraSure Technologies/ AbbVie	Co-promotion**	ODM-201, an investigational novel oral androgen receptor inhibitor (p2)	75
Orion/ Bayer	Co-development, option to co-promote in Europe	OraQuick HCV rapid test in US	68
Sorrento Therapeutics / Morphotek	Research and option agreement	To generate chemotherapeutic antibody drug conjugates (ADCs) (platform)	50
NanoString Technologies/ Celgene	Development	Development of a companion diagnostic assay	45
ECR Pharmaceuticals / Valeant	Company acquisition	Akorn subsidiary with branded generics business	41

All deals are worldwide unless otherwise noted.

* Deal terms included up to $185m milestones per product; estimated headline could be approximately $2.8bn if all products are successful.

**US only

Fuente: PMLiVE

Haciendo click en cada uno de los links siguientes, 

accederán a los Contenidos de nuestros 

TALLERES DE CAPACITACIÓN IN COMPANY A MEDIDA:

(translator on page)

Cómo INCORPORAR y APLICAR Modelos de
PENSAMIENTO ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_6246.html

Cómo GERENCIAR EFICAZMENTE a partir del

MANAGEMENT ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_3.html

Cómo GERENCIAR PROCESOS DE CAMBIO
y no sufrir en el intento

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa.html

¿Cómo IMPLEMENTAR ESTRATEGIAS EFECTIVAS?

Recetas para Escenarios Turbulentos

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-taller-de.html

Consultas al mail: msg.latam@gmail.com

ó al TE: +5411-3532-0510